查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1801912

泌尿道感染檢測市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Urinary Tract Infection Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 134 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球泌尿道感染檢測市場規模達10億美元，預計到2034年將以6.2%的複合年成長率成長，達到19億美元。該市場正在穩步擴張，主要受以下幾個核心因素驅動：全球泌尿道感染負擔的增加、醫院內感染病例的增加、發展中國家糖尿病盛行率的上升以及創新診斷解決方案的推出。由於糖尿病使人更容易患泌尿道感染，全球糖尿病患者數量的不斷成長也推動了對及時高效診斷工具的需求。

尿路感染檢測市場 - IMG1

泌尿道感染檢測是一項臨床流程，有助於檢測泌尿系統各部位（包括膀胱、尿道、腎臟和輸尿管）的感染情況。人們對早期診斷和精準治療的需求日益成長，這促使醫療保健提供者採用先進的檢測試劑盒，以支持有效的患者治療。診斷方法的持續創新有助於應對早期無症狀感染的挑戰，促進這些技術的廣泛應用，並推動醫療機構的市場擴張。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 10億美元
預測值 19億美元
複合年成長率 6.2%

尿液分析細分市場因其價格實惠、易於取得和診斷精準度高，在2024年的價值達到4.941億美元。尿液分析仍然是檢測細菌存在並指導後續臨床決策的首選初步檢測方法。老年人口的成長進一步加速了該細分市場的發展勢頭，老年人由於生理變化以及導尿管和其他干預措施的使用增多，面臨更高的尿路感染風險。

2024年，膀胱炎細分市場佔據52.1%的市佔率。膀胱炎是最常見的泌尿道感染亞型，由於生物因素，女性患者受其影響特別嚴重。患者頻繁復發，促使其持續進行重複診斷檢測，增加了相關檢測方案的採用率。同時，在健康教育計畫的支持下，大眾對膀胱炎早期症狀的認知不斷提高，鼓勵更多人尋求檢測，從而進一步加速該細分市場的成長。

2024年，北美泌尿道感染檢測市場佔36.4%的市佔率。這一領先地位得益於該地區強大的醫療基礎設施、先進醫療診斷技術的早期應用，以及美國和加拿大泌尿道感染患者群體的不斷成長。尿路感染病例的增加，尤其是在老年人、女性和患有長期疾病的人群中，正推動該地區尿路感染檢測行業的持續擴張。

活躍於全球泌尿道感染檢測市場的關鍵公司包括西門子醫療、ACON Laboratories、康德樂、Quest Diagnostics、賽默飛世爾科技、Bio-Rad Laboratories、雅培實驗室、羅氏製藥、Labcorp、朗道實驗室、Focus Laboratories 和 Mankind。為了鞏固市場地位，泌尿道感染檢測領域的領導企業正致力於透過自動化和數位化整合來提高診斷準確性並縮短檢測週轉時間。與醫療保健提供者和診斷實驗室的策略合作夥伴關係正在擴大產品可用性和客戶覆蓋範圍。各公司也大力投資研發快速檢測試劑盒和支援早期檢測的即時診斷設備。重點是開發高靈敏度的檢測方法和分子檢測，即使在無症狀病例中也能提供可靠的結果。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
    • 供應商格局
    • 每個階段的增值
    • 影響價值鏈的因素
  • 產業衝擊力
    • 成長動力
      • 全球泌尿道感染盛行率不斷上升
      • 院內後天性泌尿道感染發生率不斷上升
      • 中低收入國家糖尿病盛行率高
      • 有關尿路感染檢測產品的新產品發布
    • 產業陷阱與挑戰
      • 與泌尿道感染檢測相關的錯誤結果
      • 嚴格的監管框架
    • 市場機會
      • 快速診斷技術的擴展
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 技術和創新格局
    • 當前的技術趨勢
    • 新興技術
  • 定價分析
  • 未來市場趨勢
  • 差距分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 北美洲
    • 歐洲
    • 亞太地區
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略展望矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係和合作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按測試類型，2021 - 2034 年

  • 主要趨勢
  • 尿液分析
  • 尿液培養
  • 藥敏試驗

第6章：市場估計與預測：按檢測試劑盒類型，2021 - 2034 年

  • 主要趨勢
  • 實驗室檢測試劑盒
  • 家庭測試套件

第7章：市場估計與預測：按應用，2021 - 2034 年

  • 主要趨勢
  • 尿道炎
  • 膀胱炎
  • 腎盂腎炎

第8章：市場估計與預測：依最終用途，2021 - 2034 年

  • 主要趨勢
  • 醫院
  • 診斷實驗室
  • 居家照護環境
  • 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Abbott Laboratories
  • ACON Laboratories
  • Bio-Rad Laboratories
  • Cardinal Health
  • F. Hoffmann-La Roche
  • Focus Laboratories
  • LabCorp
  • Mankind
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthineers
  • Thermo Fisher Scientific
簡介目錄
Product Code: 5628

The Global Urinary Tract Infection Testing Market was valued at USD 1 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 1.9 billion by 2034. This market is expanding steadily, driven by several core factors such as the rising global burden of UTIs, the growing number of hospital-acquired infections, increased diabetes prevalence in developing countries, and the launch of innovative diagnostic solutions. As diabetes makes individuals more susceptible to urinary infections, the rising number of diabetic patients worldwide is fueling greater demand for timely and efficient diagnostic tools.

Urinary Tract Infection Testing Market - IMG1

UTI testing is a clinical process that helps detect infections in various parts of the urinary system, which includes the bladder, urethra, kidneys, and ureters. The growing need for early diagnosis and accurate treatment is pushing healthcare providers to adopt advanced testing kits that support effective patient outcomes. Continuous innovation in diagnostic methods is helping address the challenge of symptomless infections in early stages, promoting the wider adoption of these technologies and boosting market expansion across healthcare facilities.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1 Billion
Forecast Value$1.9 Billion
CAGR6.2%

The urinalysis segment was valued at USD 494.1 million in 2024 due to its affordability, availability, and diagnostic precision. Urinalysis remains the preferred preliminary test for detecting bacterial presence and guiding subsequent clinical decisions. The segment's momentum is further accelerated by the growing elderly population, who face a higher risk of UTIs because of physiological changes and increased use of catheters and other interventions.

The cystitis segment held a 52.1% share in 2024. Cystitis is the most widespread UTI subtype, largely impacting women due to biological factors. Frequent recurrence among patients continues to drive repeat diagnostic testing, increasing the uptake of related testing solutions. In parallel, improved public awareness around early symptoms of cystitis, supported by educational health initiatives, is encouraging more individuals to seek testing, further accelerating segment growth.

North America Urinary Tract Infection Testing Market held a 36.4% share in 2024. This leadership is attributed to the region's robust healthcare infrastructure, early adoption of advanced medical diagnostics, and a growing UTI patient population in both the US and Canada. Rising UTI cases-particularly among older adults, women, and individuals with long-term health conditions-are contributing to the sustained expansion of the UTI testing industry in the region.

Key companies active in the Global Urinary Tract Infection Testing Market include Siemens Healthineers, ACON Laboratories, Cardinal Health, Quest Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, F. Hoffmann-La Roche, Labcorp, Randox Laboratories, Focus Laboratories, and Mankind. To solidify their market position, leading players in the urinary tract infection testing space are focusing on advancing diagnostic accuracy and speeding up testing turnaround times through automation and digital integration. Strategic partnerships with healthcare providers and diagnostic labs are expanding product availability and customer reach. Companies are also heavily investing in R&D to develop rapid testing kits and point-of-care devices that support early-stage detection. Emphasis is being placed on developing high-sensitivity assays and molecular tests that deliver reliable results even in asymptomatic cases.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional
    • 2.2.2 Test type
    • 2.2.3 Test kit type
    • 2.2.4 Application
    • 2.2.5 End use
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of urinary tract infections globally
      • 3.2.1.2 Growing incidence of hospital-acquired urinary tract infection
      • 3.2.1.3 High prevalence of diabetes in low and middle-income nations
      • 3.2.1.4 Novel product launches regarding UTI testing products
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 False results associated with UTI testing
      • 3.2.2.2 Stringent regulatory framework
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of rapid diagnostic technologies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology and innovation landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Pricing analysis
  • 3.7 Future market trends
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategic outlook matrix
  • 4.7 Key developments
    • 4.7.1 Mergers and acquisitions
    • 4.7.2 Partnerships and collaborations
    • 4.7.3 New product launches
    • 4.7.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Urinalysis
  • 5.3 Urine cultures
  • 5.4 Susceptibility testing

Chapter 6 Market Estimates and Forecast, By Test Kit Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Laboratory test kits
  • 6.3 Home test kits

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Urethritis
  • 7.3 Cystitis
  • 7.4 Pyelonephritis

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Homecare settings
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 ACON Laboratories
  • 10.3 Bio-Rad Laboratories
  • 10.4 Cardinal Health
  • 10.5 F. Hoffmann-La Roche
  • 10.6 Focus Laboratories
  • 10.7 LabCorp
  • 10.8 Mankind
  • 10.9 Quest Diagnostics
  • 10.10 Randox Laboratories
  • 10.11 Siemens Healthineers
  • 10.12 Thermo Fisher Scientific